Cannabis strains — the Swiss strain hub

From Cali and Thai to Swiss indoor genetics: this hub curates our strain deep-dives, comparisons and buying checklists for the Swiss market.

The hub separates Indica, Sativa and hybrid by effect, THC/CBD ratio and typical use (sleep, focus, creativity, pain). 91 strain profiles each show terpene profile, Swiss price level and legal access routes — prescription, pilot trial or CBD variant under 1 % THC.

Definition and context

A strain is a genetically stabilised lineage with a characteristic cannabinoid and terpene profile. While the classification into Indica, Sativa, and hybrid describes growth characteristics and origin, it is only a rough guide for predicting effects.

The situation in Switzerland

In the legal Swiss market, strains are bred to be CBD-dominant: high CBD content with under 1% total THC. Consequently, famous names from the THC market often exist as CBD versions with the same aroma but a different active ingredient ratio.

What this means in practice

When choosing a strain, three criteria are more helpful than the name: cultivation method (indoor, greenhouse, outdoor), CBD content according to the analysis certificate, and dominant terpenes. Beginners are better off comparing small quantities of several chemovars rather than buying large amounts of a single strain right away.

Frequently asked questions

Are Indica strains always relaxing?

No. The classification originates from botany, not pharmacology. The terpene and cannabinoid profile provides a much more accurate indication of the effects.

Are there CBD versions of well-known strains?

Yes, many classic genetics are bred to be CBD-dominant. They retain their aroma and bud structure but remain under 1% THC.

How do I recognise indoor quality?

Dense, neatly trimmed buds, an intense aroma, visible trichomes, and a batch certificate declaring the cultivation method.

Background and development

Switzerland's relationship with cannabis strains transformed in 2011 when the federal threshold for illegal THC was set at 1.0% under the Narcotics Act, also known as BetmG. This pragmatism sparked a legal CBD market, regulated by the Federal Office of Public Health and Swissmedic, encouraging local growers to breed high-CBD, low-THC strains. While the general market remains bound to this 1% threshold, a major shift occurred on 1 August 2022, when medical cannabis was simplified, transferring prescription authority directly to doctors without requiring exceptional permits. Simultaneously, Switzerland launched pilot studies, such as Weed Care in Basel, Züri Can in Zurich, and trials in Bern, Lausanne, and Geneva, to study regulated sales of high-THC strains. Today, Swiss consumers navigate a dual reality of a flourishing legal CBD market under the 1% THC limit and highly regulated municipal pilots paving the way for future recreational frameworks.

Distinctions and misconceptions

A common misconception in the Swiss market is confusing cannabis strains with product types or preparation methods. Consumers often conflate a strain name with its final physical form, such as flowers, hashish, or extracts. However, a strain refers exclusively to the plant genetics, whereas these products are processing methods. Another frequent error is equating legal CBD strains with complete immunity under road traffic laws. While Swiss law permits CBD cannabis containing under 1.0% THC, consuming these strains can still cause blood concentrations to exceed the strict Swiss road safety limit of 1.5 micrograms of THC per litre of blood. Additionally, people confuse legal CBD strains with the decriminalised possession rule: carrying up to 10 grams of high-THC cannabis is a minor offence carrying a CHF 100 fixed penalty, whereas possessing certified legal CBD under the 1% threshold is entirely legal and subject to no penalty.

Decision guide for Switzerland

When selecting a strain at CannabisClub.ch, adult members must align their choice with their personal environment and local laws. First, verify the official certificate of analysis to confirm the total THC content remains strictly below 1.0% to avoid violating the Narcotics Act. Next, evaluate the terpene profile rather than relying on marketing labels; look for transparent lab testing certifying the absence of heavy metals and synthetic cannabinoids. For budget considerations, legal Swiss indoor flowers typically command higher prices than outdoor or greenhouse options due to the resource-intensive cultivation involved. Avoid purchasing from unverified sources on the street where cannabinoid ratios are unknown, genetics are unstable, and contamination risks are high. Instead, choose certified Swiss-grown chemovars that provide full traceability from seed to shelf, ensuring your selection matches both your sensory preferences and Switzerland’s rigorous consumer safety standards.

What is the legal distinction between high-THC strains and CBD strains in Swiss public spaces?

Under Swiss law, strains containing less than 1.0% total THC are classified as legal CBD. You can consume and possess them freely. Conversely, strains exceeding 1% THC remain illegal for general public possession. However, carrying up to 10 grams of high-THC cannabis is treated as a minor infraction, typically resulting in a CHF 100 fixed penalty rather than criminal prosecution.

Can I legally grow any cannabis strain at home in Switzerland?

You may legally cultivate cannabis strains at home only if they remain strictly under the 1.0% total THC threshold. Cultivating high-THC strains at home for recreational use remains illegal under the Narcotics Act, outside of official canton-approved pilot studies. Ensure you source certified low-THC seeds or cuttings that guarantee compliance with federal regulations to avoid legal complications.

Explore this topic further

These guides explain the background and address practical questions in the Swiss context.

Key figures

  • 220’000+ — Swiss adults regularly consume cannabis (BAG · Suchtmonitoring 2024)
  • 36% — of 15–34 year-olds have tried cannabis (EMCDDA · Country Report Switzerland 2024)
  • CHF 582M — estimated Swiss cannabis black-market revenue per year (Uni Genf · Cannabis Market Estimate 2023)
  • 7 — cities with active or approved pilot projects (BAG · Cannabis Pilotversuche 2026)

Current research

  • Cannabis use in Switzerland — Addiction Monitoring 2024 — Sucht Schweiz, BAG · 2024
  • European Drug Report — Cannabis Chapter — EMCDDA, EUDA · 2024
  • WHO Expert Committee on Drug Dependence — Cannabis Review — WHO ECDD, WHO · 2023